Study Title and Description
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Key Questions Addressed
|2||Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?|
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.|
|Author||Barrett-Connor E., Mosca L., Collins P., Geiger MJ., Grady D., Kornitzer M., McNabb MA., Wenger NK.|
|Country||Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093-0607, USA. firstname.lastname@example.org|
Pubmed ID: 16837676
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.